Donor cells take on viruses in transplant patients

NCT ID NCT03665675

Recruiting now Disease control Sponsor: Sumithira Vasu Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 21, 2026 · Updated 22 times

Summary

This early-phase study tests whether specially trained white blood cells from a donor can safely control or clear cytomegalovirus (CMV) or adenovirus infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-fighting cells and be monitored for side effects and infection response. The goal is to manage the virus without relying on long-term antiviral drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nationwide Children's Hospital
RECRUITING

Columbus, Ohio, 43205, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ohio State University Comprehensive Cancer Center
SUSPENDED

Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.

ADENOVIRUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT CYTOMEGALOVIRUS DONOR SOLID ORGAN TRANSPLANTATION RECIPIENT SOLID ORGAN TRANSPLANTATION RECIPIENT